Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.

Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019 Mar 27;: Authors: Papamichael K, Cheifetz AS, Melmed GY, Irving PM, Casteele NV, Kozuch PL, Raffals LE, Baidoo L, Bressler B, Devlin SM, Jones J, Kaplan GG, Sparrow MP, Velayos FS, Ullman T, Siegel CA Abstract BACKGROUND & AIMS: Therapeutic drug monitoring (TDM) is widely available for biologic therapies in patients with inflammatory bowel disease (IBD). We reviewed current data and provided expert opinion regarding the clinical utility of TDM for biologic therapies…

Read More

A Nomogram Combining Fecal Calprotectin Levels and Plasma Cytokine Profiles for Individual Prediction of Postoperative Crohn’s Disease Recurrence.

A Nomogram Combining Fecal Calprotectin Levels and Plasma Cytokine Profiles for Individual Prediction of Postoperative Crohn’s Disease Recurrence. Inflamm Bowel Dis. 2019 Mar 29;: Authors: Cerrillo E, Moret I, Iborra M, Pamies J, Hervás D, Tortosa L, Sáez-González E, Nos P, Beltrán B Abstract BACKGROUND: The aims of this study were to characterize the immune response profile in patients with Crohn’s disease (CD) and early postoperative recurrence (POR), to identify predictive biomarkers, and to develop a noninvasive predictive tool for individual estimation of POR risk. METHODS: Sixty-one patients who had…

Read More

Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission-confounded by the gut microbiome?

Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission-confounded by the gut microbiome? Aliment Pharmacol Ther. 2019 Apr;49(8):1086-1087 Authors: Leong RWL, Kaakoush NO, Yau YY, Wasinger VC PMID: 30920041 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30920041?dopt=Abstract

Read More

Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission – confounded by the gut microbiome? Authors’ reply.

Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission – confounded by the gut microbiome? Authors’ reply. Aliment Pharmacol Ther. 2019 Apr;49(8):1088-1089 Authors: Keshteli AH, Madsen KL, Mandal R, Boeckxstaens GE, Bercik P, De Palma G, Reed DE, Wishart D, Vanner S, Dieleman LA PMID: 30920043 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30920043?dopt=Abstract

Read More

Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission – confounded by the gut microbiome? Authors’ reply.

Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission – confounded by the gut microbiome? Authors’ reply. Aliment Pharmacol Ther. 2019 Apr;49(8):1087-1088 Authors: Bond A, Probert C PMID: 30920048 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30920048?dopt=Abstract

Read More

Molecular Profiling of Ulcerative Colitis Subjects from the TURANDOT Trial Reveals Novel Pharmacodynamic/Efficacy Biomarkers.

Molecular Profiling of Ulcerative Colitis Subjects from the TURANDOT Trial Reveals Novel Pharmacodynamic/Efficacy Biomarkers. J Crohns Colitis. 2019 Mar 19;: Authors: Zhou H, Xi L, Ziemek D, O’Neil S, Lee J, Stewart Z, Zhan Y, Zhao S, Zhang Y, Page K, Huang A, Maciejewski M, Zhang B, Gorelick KJ, Fitz L, Pradhan V, Cataldi F, Vincent M, Von Schack D, Hung K, Hassan-Zahraee M Abstract BACKGROUND AND AIMS: To define pharmacodynamic and efficacy biomarkers in ulcerative colitis [UC] patients treated with PF-00547659, an anti-human mucosal addressin cell adhesion molecule-1 [MAdCAM-1]…

Read More

The cost-effectiveness of biological therapy cycles in the management of Crohn’s disease.

The cost-effectiveness of biological therapy cycles in the management of Crohn’s disease. J Crohns Colitis. 2019 Mar 20;: Authors: Bolin K, Hertervig E, Louis E Abstract OBJECTIVES: to examine the cost-effectiveness of continued treatment for patients with moderate-severe Crohn’s disease in clinical remission, with a combination of anti-TNFα (infliximab) and immunomodulator therapy compared to two different withdrawal strategies (1) withdrawal of the anti-TNFα therapy, and (2) withdrawal of the immunomodulator therapy, respectively. MATERIAL AND METHODS: A decision-tree model was constructed mimicking three treatment arms: (1) continued combination therapy with infliximab…

Read More

Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn’s disease patients.

Related Articles Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn’s disease patients. World J Gastroenterol. 2019 Mar 14;25(10):1266-1277 Authors: Foster AJ, Smyth M, Lakhani A, Jung B, Brant RF, Jacobson K Abstract BACKGROUND: Asymptomatic children with Crohn’s disease (CD) require ongoing monitoring to ensure early recognition of a disease exacerbation. AIM: In a cohort of pediatric CD patients, we aimed to assess the utility of serial fecal calprotectin measurements to detect intestinal inflammatory activity and predict disease relapse. METHODS: In this prospective longitudinal cohort study, children with CD…

Read More

Clinical Practice Guideline for the Management of Luminal Crohn’s Disease: The Toronto Consensus.

Related Articles Clinical Practice Guideline for the Management of Luminal Crohn’s Disease: The Toronto Consensus. Clin Gastroenterol Hepatol. 2019 Mar 07;: Authors: Panaccione R, Steinhart AH, Bressler B, Khanna R, Marshall JK, Targownik L, Afif W, Bitton A, Borgaonkar M, Chauhan U, Halloran B, Jones J, Kennedy E, Leontiadis GI, Loftus EV, Meddings J, Moayyedi P, Murthy S, Plamondon S, Rosenfeld G, Schwartz D, Seow CH, Williams C, Bernstein CN Abstract BACKGROUND & AIMS: Crohn’s disease (CD) is a lifelong illness with substantial morbidity, although new therapies and treatment paradigms…

Read More
<< Go Back